Likewise, preliminary data derived from a phase I/II trial with PD-L1-refractory melanoma (ILLUMINATE 301) showed maturation of myeloid type 1 DCs (mDC1s) in response to an intratumorally administered synthetic TLR-9 agonist (IMO-2125, tilsotolimod) in combination with CTLA-4 blocking. The gene discussed is TLR9; the disease is melanoma.